Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model
Lukmanee Tradtrantip, Nithi Asavapanumas, Puay-Wah Phuan, A S Verkman, Lukmanee Tradtrantip, Nithi Asavapanumas, Puay-Wah Phuan, A S Verkman
Abstract
Neuromyelitis optica (NMO) is an autoimmune demyelinating disease of the central nervous system in which binding of anti-aquaporin-4 (AQP4) autoantibodies (NMO-IgG) to astrocytes causes complement-dependent cytotoxicity (CDC) and inflammation resulting in oligodendrocyte and neuronal injury. There is compelling evidence for a central role of complement in NMO pathogenesis. Here, we evaluated the potential of C1-esterase inhibitor (C1-inh) for complement-targeted therapy of NMO. C1-inh is an anti-inflammatory plasma protein with serine protease inhibition activity that has a broad range of biological activities on the contact (kallikrein), coagulation, fibrinolytic and complement systems. C1-inh is approved for therapy of hereditary angioedema (HAE) and has been studied in a small safety trial in acute NMO relapses (NCT 01759602). In vitro assays of NMO-IgG-dependent CDC showed C1-inh inhibition of human and rat complement, but with predicted minimal complement inhibition activity at a dose of 2000 units in humans. Inhibition of complement by C1-inh was potentiated by ∼10-fold by polysulfated macromolecules including heparin and dextran sulfate. In rats, intravenous C1-inh at a dose 30-fold greater than that approved to treat HAE inhibited serum complement activity by <5%, even when supplemented with heparin. Also, high-dose C1-inh did not reduce pathology in a rat model of NMO produced by intracerebral injection of NMO-IgG. Therefore, although C1r and C1s are targets of C1-inh, our in vitro data with human serum and in vivo data in rats suggest that the complement inhibition activity of C1-inh in serum is too low to confer clinical benefit in NMO.
Trial registration: ClinicalTrials.gov NCT01759602.
Conflict of interest statement
Competing Interests: This work described in this manuscript was funded, in part, by a sponsored research agreement from a commercial source (CSL Behring). This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Figures
References
- Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6: 805–815.
- Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, et al. (2013) Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 84: 922–930.
- Jarius S, Paul F, Franciotta D, Waters P, Zipp F, et al. (2008) Mechanism of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4: 202–214.
- Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473–477.
- Papadopoulos MC, Verkman AS (2012) Aquaporin water channels in the nervous system. Nat Rev Neurosci 14: 265–277.
- Papadopoulos MC, Verkman AS (2013) Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11: 535–544.
- Kira J (2011) Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders. J Neurol Sci 311: 69–77.
- Collongues N, de Seze J (2011) Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 4: 111–121.
- Cree B (2008) Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep 8: 427–433.
- Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, et al. (2013) Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody level. J Clin Neurol 9: 36–42.
- Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, et al. (2002) A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125: 1450–1461.
- Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, et al. (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224–1234.
- Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, et al. (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130: 1194–1205.
- Sabater L, Giralt A, Boronat A, Hankiewicz K, Blanco Y, et al. (2009) Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol 215: 31–35.
- Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, et al. (2007) Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69: 2221–2231.
- Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, et al. (2009) Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol 66: 1164–1167.
- Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, et al. (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66: 617–629.
- Zhang H, Bennett JL, Verkman AS (2011) Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 70: 943–954.
- Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, et al. (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133: 349–361.
- Asavapanumas N, Ratelade J, Verkman AS (2014) Unique neuromyelitis optica pathology produced in naòve rats by intracerebral administration of NMO-IgG. Acta Neuropathol 127: 539–551.
- Pittock SJ, Lennon VA, Mckeon A, Mandrekar J, Weinshenker BG, et al. (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12: 554–562.
- Parker C (2009) Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373: 759–767.
- Phuan PW, Zhang H, Asavapanumas N, Leviten M, Rosenthal A, et al. (2013) C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol 125: 829–840.
- Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, et al. (2000) C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of disease other than hereditary angioedema. Pharmacol Rev 52: 91–112.
- Karnaukhova E (2013) C1-esterase inhibitor: biological activities and therapeutic applications. J Hematol Thromb Dis 1: 3 Available: .
- Levy M, Mealy MA (2014) Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neutoinflamm 1 doi
- Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS (2012) Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem 287: 13829–13839.
- Gettins PG (2002) Serpin structure, mechanism, and function. Chem Rev 102: 4751–4804.
- Ziccardi RJ, Cooper NR (1979) Active disassembly of the first complement component, C1, by C1 inactivator. J Immunol 123: 788–792.
- Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP (1992) Heparin and modified heparin inhibit complement activation in vivo. J Immunol 148: 3210–3215.
- Garlatti V, Chouquet A, Lunardi T, Vives R, Paidassi H, et al. (2010) Cutting edge: C1q binds deoxyribose and heparin sulfate through neighboring sites of its recognition domain. J Immunol 185: 808–812.
- Hughes-Jones NC, Gardner B (1978) The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules. Immunol 34: 459–463.
- Wuillemin WA, Velthuis HT, Lubbers YTP, de Ruig CP, Eldering E, et al. (1997) Potentiation of C1 inhibitor by glycosaminoglycans. J Immunol 159: 1953–1960.
- Beinrohr L, Harmat V, Dobo J, Lorincz Z, Gal P, et al. (2007) C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 282: 21100–21109.
- Ratelade J, Smith AJ, Verkman AS (2014) Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Exper Neurol 255: 145–153.
- Crane JM, Lam C, Rossi A, Gupta T, Bennett JL, et al. (2011) Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. J Biol Chem 286: 16516–16524.
- Ayzenberg I, Kleiter I, Schruder A, Hellwig K, Chan A, et al. (2013) Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70: 394–397.
- Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, et al. (2012) Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71: 314–322.
- Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, et al. (2012) Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol 71: 323–33.
- Zhang H, Verkman AS (2013) Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 123: 2306–2316.
- Kerr FK, Thomas AR, Wijeyewickrema LC, Whisstock JC, Boyd SE, et al. (2008) Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor. Mol Immunol 45: 670–677.
- Prematta MJ, Prematta T, Craig TJ (2008) Treatment of hereditary angioedema with plasma-derived C1 inhibitor. Ther Clin Risk Manag 4: 975–982.
- Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M (2009) C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trend Mol Med 15: 69–78.
- Ratelade J, Verkman AS (2014) Inhibitors of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica. Mol Immunol 62: 104–113.
- Cicardi M, Bergamaschini L, Cugno M, Beretta A, Zingale LC, et al. (1998) Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiol 199: 366–376.
- Kunschak M, Engl W, Maritsch F, Rosen FS, Eder G, et al. (1998) A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 38: 540–549.
- Wouters D, Stephan F, Strengers P, Hass MD, Brouwer C, et al. (2013) C1-esterase inhibitor concentrate rescues erythrocyte from complement-mediated destruction in autoimmune hemolytic anemia. Blood 121: 1242–1244.
- Bianchino AC, Poon PH, Schumaker VN (1988) A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor. J Immunol 141: 3930–3936.
- Nielsen EW, Waage C, Fure H, Brekke OL, Sfyroera G (2007) Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Mol Imunol 44: 1819–1826.
- Tenner AJ, Frank MM (1986) Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1. J Immunol 137: 625–630.
Source: PubMed